MedTrace Logo

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

NCT00026429 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-12-18

No results posted yet for this study

Summary

RATIONALE: Biological therapies such as denileukin diftitox may be able to deliver cancer-killing substances directly to non-Hodgkin's lymphoma cells.

PURPOSE: Phase II trial to study the effectiveness of denileukin diftitox in treating patients who have non-Hodgkin's lymphoma.

Conditions

Interventions

BIOLOGICAL

denileukin diftitox

Sponsors & Collaborators

  • Pharmatech Oncology

    lead INDUSTRY

Principal Investigators

  • Debby Henkens · Pharmatech Oncology

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00026429 on ClinicalTrials.gov